Bio-Rad Laboratories, Inc. (BIO)
Bio-Rad Laboratories, Inc. (BIO) is a healthcare company (medical devices) based in the United States. The share price is $359.15, down 0.31% on the day, which values the company at $9.66B. Price as of 17 Nov 2026, 18:19 UTC, from Yahoo Finance.
Key facts
- Share price
- $359.15−0.31% today
- Market value
- $9.66B
- P/E ratio
- 9.5×last 12 months
- Forward P/E
- 36.3×
- Funk Score
- 38/100
- Against its own history
- Below its usual priceusual price $465.05
- 200-week average
- $325.5910% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Bio-Rad Laboratories, Inc. in more detail
BIO trades at 9.5× its last twelve months' earnings, 36.3× next year's expected earnings, 3.7× sales. Measured against its own history, the price is 23% below what its usual multiples would imply ($465.05) — below its usual price. It sits 10% above its 200-week average of $325.59.
Over the last five fiscal years Bio-Rad Laboratories, Inc. has compounded revenue 0.3% a year, earnings per share -26.1% a year, free cash flow -4.7% a year. Its Funk Score is 38 out of 100 (financial strength 5.4, profitability 3.3, growth 1.1, value 5.2, each out of 10).
In its favour: Altman Z in the safe zone; Share count keeps falling. Worth checking: Low return on invested capital.
3 of the superinvestors tracked here hold BIO, including John Rogers (3.1% of the portfolio), Matthew McLennan (1.5% of the portfolio), Steven Romick (1.2% of the portfolio).
Superinvestors holding BIO
3 of the investors tracked here report a position in their latest 13F filing.
- John Rogers Ariel Investments3.10% of portfolio · $298.1M · trimmed · Q3 2026
- Matthew McLennan First Eagle Investment Management1.46% of portfolio · $927.5M · trimmed · Q3 2026
- Steven Romick First Pacific Advisors (FPA)1.21% of portfolio · $101.6M · trimmed · Q3 2026
Health Care companies of similar size
- Bio-TechneTECH
- BioMarin PharmaceuticalBMRN
- AvantorAVTR
- Ensign GroupENSG
- VaxcytePCVX
- Molina HealthcareMOH
- Spyre TherapeuticsSYRE
- QiagenQGEN
- InsuletPODD
- BrukerBRKR
- Globus MedicalGMED
- Madrigal PharmaceuticalsMDGL
Side by side:BIO vs PCVX (Bio-Rad Laboratories, Inc. vs Vaxcyte)BIO vs MOH (Bio-Rad Laboratories, Inc. vs Molina Healthcare)BIO vs ENSG (Bio-Rad Laboratories, Inc. vs Ensign Group)BIO vs SYRE (Bio-Rad Laboratories, Inc. vs Spyre Therapeutics)BIO vs QGEN (Bio-Rad Laboratories, Inc. vs Qiagen)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Bio-Rad Laboratories, Inc. (BIO): questions and answers
What is BIO's P/E ratio?
Bio-Rad Laboratories, Inc. trades at 9.5× its last twelve months' earnings and 36.3× next year's expected earnings. At its fiscal year-ends over the past 15 years the P/E ranged from 4.6× to 207.1×, with a median of 18.5×.
What is BIO's PEG ratio?
Bio-Rad Laboratories, Inc.'s PEG ratio is 4.01 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Bio-Rad Laboratories, Inc.'s market cap?
Bio-Rad Laboratories, Inc. is valued at $9.66B at a share price of $359.15.
Is BIO overvalued or undervalued?
Against its own history, BIO is below its usual price: the price is 23% below the $465.05 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is BIO above its 200-week moving average?
Yes. BIO is 10.3% above its 200-week average of $325.59. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Bio-Rad Laboratories, Inc. growing?
Over the last five fiscal years Bio-Rad Laboratories, Inc.'s revenue grew 0.3% a year and its earnings per share -26.1% a year; over ten years revenue grew 2.5% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Bio-Rad Laboratories, Inc. (BIO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BIO
Underlying data: Yahoo Finance; company filings with the SEC.